uniQure Revenue and Competitors

Amsterdam, Netherlands

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • uniQure's estimated annual revenue is currently $500.4M per year.(i)
  • uniQure's estimated revenue per employee is $712,821
  • uniQure's current valuation is $934M. (January 2022)

Employee Data

  • uniQure has 702 Employees.(i)
  • uniQure grew their employee count by 5% last year.

uniQure's People

NameTitleEmail/Phone
1
Executive Assistant to Chief Medical Officer and SVP, Regulatory AffairsReveal Email/Phone
2
Chief People and Culture Officer (Interim)Reveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
CEOReveal Email/Phone
5
Biosafety officerReveal Email/Phone
6
Executive Assistant To CEO and Chief Legal OfficerReveal Email/Phone
7
VP Global Manufacturing OperationsReveal Email/Phone
8
VP, New Product Planning (Global and US Commercialization Strategy)Reveal Email/Phone
9
Head CommercialReveal Email/Phone
10
VP, LegalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M45-34%N/AN/A
#2
$10.4M67-7%N/AN/A
#3
$10.2M666%N/AN/A
#4
$6.7M43-2%N/AN/A
#5
$23.3M150-18%N/AN/A
#6
$35.8M2319%N/AN/A
#7
$11.2M72-18%N/AN/A
#8
$15.2M983%N/AN/A
#9
$1.7M11-52%N/AN/A
#10
$10.1M657%N/AN/A
Add Company

What Is uniQure?

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

keywords:N/A

N/A

Total Funding

702

Number of Employees

$500.4M

Revenue (est)

5%

Employee Growth %

$934M

Valuation

N/A

Accelerator

uniQure News

2022-04-19 - Form PRE 14A uniQure NV For: Jun 14

On behalf of the Board of Directors of uniQure N.V. (the “Company”), I invite you to attend our 2022 Annual General Meeting of Shareholders...

2022-04-06 - uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

uniQure N.V. (NASDAQ:QURE) is a great speculative biotech to look into. The reason why I state this is because its main clinical program,...

2022-03-30 - CSL, uniQure's gene therapy for hemophilia B under review in ...

The multi-year clinical development was led by uniQure (NASDAQ:QURE) and sponsorship of the trials in the U.S. has transitioned to CSL Behring...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$128.3M70545%N/A
#2
$3.5M71433%N/A
#3
$272.2M7207%N/A
#4
$206.9M7216%N/A
#5
$212.3M72210%N/A